623 related articles for article (PubMed ID: 28228394)
21. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine.
Kari L; Whitmire WM; Crane DD; Reveneau N; Carlson JH; Goheen MM; Peterson EM; Pal S; de la Maza LM; Caldwell HD
J Immunol; 2009 Jun; 182(12):8063-70. PubMed ID: 19494332
[TBL] [Abstract][Full Text] [Related]
22. Validation of the Chlamydia trachomatis genital challenge pig model for testing recombinant protein vaccines.
Schautteet K; Stuyven E; Cox E; Vanrompay D
J Med Microbiol; 2011 Jan; 60(Pt 1):117-127. PubMed ID: 20847123
[TBL] [Abstract][Full Text] [Related]
23. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.
He Q; Martinez-Sobrido L; Eko FO; Palese P; Garcia-Sastre A; Lyn D; Okenu D; Bandea C; Ananaba GA; Black CM; Igietseme JU
Immunology; 2007 Sep; 122(1):28-37. PubMed ID: 17451464
[TBL] [Abstract][Full Text] [Related]
24. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection.
Singh SR; Hulett K; Pillai SR; Dennis VA; Oh MK; Scissum-Gunn K
Vaccine; 2006 Feb; 24(8):1213-24. PubMed ID: 16194585
[TBL] [Abstract][Full Text] [Related]
25. A new murine model for testing vaccines against genital Chlamydia trachomatis infections in males.
Pal S; Sarcon AK; de la Maza LM
Vaccine; 2010 Nov; 28(48):7606-12. PubMed ID: 20920574
[TBL] [Abstract][Full Text] [Related]
26. Chlamydia trachomatis infection control programs: lessons learned and implications for vaccine development.
Chavez JM; Vicetti Miguel RD; Cherpes TL
Infect Dis Obstet Gynecol; 2011; 2011():754060. PubMed ID: 22144851
[TBL] [Abstract][Full Text] [Related]
27. The mucosal immune response to Chlamydia trachomatis infection of the reproductive tract in women.
Agrawal T; Vats V; Salhan S; Mittal A
J Reprod Immunol; 2009 Dec; 83(1-2):173-8. PubMed ID: 19896206
[TBL] [Abstract][Full Text] [Related]
28. Development status and future prospects for a vaccine against Chlamydia trachomatis infection.
Hafner LM; Wilson DP; Timms P
Vaccine; 2014 Mar; 32(14):1563-71. PubMed ID: 23973245
[TBL] [Abstract][Full Text] [Related]
29. Chlamydia trachomatis infection: incidence, health costs and prospects for vaccine development.
Beagley KW; Timms P
J Reprod Immunol; 2000 Aug; 48(1):47-68. PubMed ID: 10996382
[TBL] [Abstract][Full Text] [Related]
30. Intramuscular Immunisation with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies.
Badamchi-Zadeh A; McKay PF; Holland MJ; Paes W; Brzozowski A; Lacey C; Follmann F; Tregoning JS; Shattock RJ
PLoS One; 2015; 10(10):e0141209. PubMed ID: 26501198
[TBL] [Abstract][Full Text] [Related]
31. Chlamydia trachomatis infection: host immune responses and potential vaccines.
Hafner L; Beagley K; Timms P
Mucosal Immunol; 2008 Mar; 1(2):116-30. PubMed ID: 19079169
[TBL] [Abstract][Full Text] [Related]
32. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection.
Whittum-Hudson JA; An LL; Saltzman WM; Prendergast RA; MacDonald AB
Nat Med; 1996 Oct; 2(10):1116-21. PubMed ID: 8837610
[TBL] [Abstract][Full Text] [Related]
33. DNA plasmid vaccine carrying Chlamydia trachomatis (Ct) major outer membrane and human papillomavirus 16L2 proteins for anti-Ct infection.
Wang L; Cai Y; Xiong Y; Du W; Cen D; Zhang C; Song Y; Zhu S; Xue X; Zhang L
Oncotarget; 2017 May; 8(20):33241-33251. PubMed ID: 28402260
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B virus core antigen as a carrier for Chlamydia trachomatis MOMP multi-epitope peptide enhances protection against genital chlamydial infection.
Jiang P; Du W; Xiong Y; Lv Y; Feng J; Zhu S; Xue X; Chen S; Zhang L
Oncotarget; 2015 Dec; 6(41):43281-92. PubMed ID: 26657117
[TBL] [Abstract][Full Text] [Related]
35. Induction of protective immunity against a Chlamydia trachomatis genital infection in three genetically distinct strains of mice.
Pal S; Peterson EM; de la Maza LM
Immunology; 2003 Nov; 110(3):368-75. PubMed ID: 14632665
[TBL] [Abstract][Full Text] [Related]
36. Chlamydia trachomatis vaccine research through the years.
Schautteet K; De Clercq E; Vanrompay D
Infect Dis Obstet Gynecol; 2011; 2011():963513. PubMed ID: 21747646
[TBL] [Abstract][Full Text] [Related]
37. Vaccination of newborn mice induces a strong protective immune response against respiratory and genital challenges with Chlamydia trachomatis.
Pal S; Peterson EM; de la Maza LM
Vaccine; 2005 Nov; 23(46-47):5351-8. PubMed ID: 16085340
[TBL] [Abstract][Full Text] [Related]
38. GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis.
Lu H; Xing Z; Brunham RC
J Immunol; 2002 Dec; 169(11):6324-31. PubMed ID: 12444139
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of tandem Chlamydia trachomatis MOMP multi-epitopes vaccine in BALB/c mice model.
Jiang P; Cai Y; Chen J; Ye X; Mao S; Zhu S; Xue X; Chen S; Zhang L
Vaccine; 2017 May; 35(23):3096-3103. PubMed ID: 28456528
[TBL] [Abstract][Full Text] [Related]
40. Protection of pigs against Chlamydia trachomatis challenge by administration of a MOMP-based DNA vaccine in the vaginal mucosa.
Schautteet K; Stuyven E; Beeckman DS; Van Acker S; Carlon M; Chiers K; Cox E; Vanrompay D
Vaccine; 2011 Feb; 29(7):1399-407. PubMed ID: 21195805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
